Teclistamab Reviewed as Potential Treatment Option in Relapsed/Refractory Multiple Myeloma

Publication
Article
ONCOLOGY® CompanionONCOLOGY® Companion, Volume 37, Supplement 9
Volume 37
Issue 9
Pages: 26-27

CancerNetwork hosted a Training Academy focused on sequencing therapies for patients with multiple myeloma who are treated with bispecific antibodies.


CancerNetwork hosted a Training Academy focused on sequencing therapies for patients with multiple myeloma who are treated with bispecific antibodies.

CancerNetwork hosted a Training Academy focused on sequencing therapies for patients with multiple myeloma who are treated with bispecific antibodies.

CancerNetwork hosted a Training Academy focused on sequencing therapies for patients with multiple myeloma who are treated with bispecific antibodies.

Available Treatment Options

  • For patients who relapse, several treatment options are available in the realm of:
    • Proteasome inhibitors
    • Bortezomib (Velcade) or carfilzomib (Kyprolis)
    • Immunomodulatory drugs
    • Lenalidomide (Revlimid), pomalidomide (Pomalyst), or daratumumab (Darzalex)
    • Other CD38 antibodies
  • For patients who relapse late, treatment options include chimeric antigen (CAR) T-cell therapies such as:
  • Idecabtagene vicleucel (Abecma) or ciltacabtagene autoleucel (Carvykti)


Teclistamab in Relapsed/Refractory Multiple Myeloma

  • It was recently approved in the United States under the same indication as CAR T-cell therapy.1
  • The trial that led to the approval was the phase 1/2 MajesTEC-1 trial (NCT03145181; NCT04557098).2
  • The risk of cytokine release syndrome (CRS) is prevalent during the first few doses, and step-up dosing should be given.
  • Patients should be hospitalized when teclistamab is given initially to monitor for adverse effects (AEs).
  • The treatment is given subcutaneously but also indefinitely, which can increase the chance of developing long-term AEs.

AE Management

  • For CRS, tocilizumab (Actemra) can be given to mitigate the AEs. However, most institutions or centers will hold off on tocilizumab if CRS is grade 1 and will observe the patient’s response before immediately treating.
    • Some will start treatment when a fever becomes present to stop it from progressing and allow more hospital beds to become available, as teclistamab must be given in an inpatient setting.

Looking Forward

  • Elranatamab (Elrexfio) was evaluated in the phase 1 MAGNETISMM-1 trial (NCT03269136), in which observed that 53% of patients who were given prior BCMA therapy responded to treatment.3
  • ABBV-383 antibody and linvoseltamab have shown similar efficacy for the indicated population.
  • Experts hope to keep studying these treatments in earlier lines of therapy to see whether higher responses can be reached.

References

  1. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. News release. FDA. October 25, 2022. Accessed August 24, 2023. https://bit.ly/3Fgsi4s
  2. Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495-505. doi:10.1056/NEJMoa2203478
  3. Raje N, Bahlis NJ, Costello C, et al. Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma. Blood. 2022;140(suppl 1):388-390. doi:10.1182/blood-2022-166494
Recent Videos
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content